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Abstract 
Influenza viruses have periodically caused pandemic due to frequent mutation of viral proteins. Influenza viruses have 
two major membrane glycoproteins: hemagglutinin (HA) and neuraminidase (NA). Hemagglutinin plays a crucial 
role in viral entry, while NA is involved in the process of a viral escape. In terms of developing antiviral drugs, HA is a 
more important target than NA in the prevention of pandemic, since HA is likely to change the host specificity of a 
virus by acquiring mutations, thereby to increase the risk of pandemic. To characterize mutated HA functions, cur-
rent approaches require immobilization of purified HA on plastic wells and carriers. These troublesome methods 
make it difficult to respond to emerging mutations. In order to address this problem, a yeast cell surface engineering 
approach was investigated. Using this technology, human HAs derived from various H1N1 subtypes were successfully 
and rapidly displayed on the yeast cell surface. The yeast-displayed HAs exhibited similar abilities to native influenza 
virus HAs. Using this system, human HAs with 190E and 225G mutations were shown to exhibit altered recognition 
specificities from human to avian erythrocytes. This system furthermore allowed direct measurement of HA binding 
abilities without protein purification and immobilization. Coupled with the ease of genetic manipulation, this system 
allows the simple and comprehensive construction of mutant protein libraries on yeast cell surface, thereby contrib-
uting to influenza virus pandemic prevention.
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Introduction
Influenza viruses have caused pandemic in humans as well 
as in animals (Potter 2001; Capua and Alexander 2008). 
The human influenza viruses recognize human-specific 
cell receptors via α2,6-linked sialic acid side chains on 
surface glycoproteins, while avian influenza viruses rec-
ognize avian-specific cell receptors via α2,3-linked sialic 
acid side chains on surface glycoproteins (Gagneux et al. 
2003; Ito and Kawaoka 2000). These subtle differences in 
sialic acid recognition are key in preventing animal influ-
enza viruses from infecting humans; however, some influ-
enza viruses infecting animals have acquired the potency 
to overcome this difference (Van Reeth 2007). Highly 
pathogenic avian influenza viruses including H5N1 sub-
types have been reported to alter their targets from avian 
to human, causing 447 deaths until 2010 (Webby and 
Webster 2003; WHO 2015). Recently, the swine influenza 
virus also acquired the ability to infect humans via genetic 
re-assortment (Zhou et  al. 1999). The swine influenza 
virus was transmitted widely among humans, resulting 
in the first influenza pandemic in the twenty first century 
(Kuiken et  al. 2011). Swine may play roles as intermedi-
ate hosts for influenza viruses between humans and avian 
species because swine cell receptors have both the α2,6- 
and the α2,3-linked sialic acid side chains on their sur-
face glycoproteins (Ito and Kawaoka 2000). When human 
influenza viruses and avian influenza viruses infect the 
same intermediate host, gene re-arrangement between 
the human and avian influenza viruses is likely to occur, 
enabling the viruses to alter their recognition preferences 
of sialic acid on surface glycoprotein (Dawood et al. 2009). 
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Indeed, the influenza virus pandemic is thought to have 
emerged from gene re-assortment of the North American 
H3N2 human-like viruses and the H1N2 swine viruses 
with Eurasian avian-like swine viruses (Dawood et  al. 
2009). The re-assortment process enables animal influ-
enza viruses to effectively develop the capacity to infect 
humans (Zhou et al. 1999), which suggests that the threat 
of infection caused by new influenza viruses will continue 
as the differences between human and animal viruses are 
overcome.
Influenza viruses have two major surface membrane 
glycoproteins: neuraminidase (NA) and hemagglutinin 
(HA) (Air and Laver 1989; Skehel and Wiley 2000). While 
NA is involved in the process by which newly generated 
viruses escape from host cells (Air and Laver 1989), HA, 
which forms a trimer embedded on the viral envelope 
surface, is responsible for binding and entry into host 
cells (Skehel and Wiley 2000). Each monomer of HA is 
synthesized as a single polypeptide (HA0) that is cleaved 
by host proteases into two subunits (HA1 and HA2) (Ske-
hel and Wiley 2000), of which HA1 represents an active 
head region that binds to sialic acid side chains on sur-
face glycoproteins and HA2 represents a stem region that 
is required for membrane fusion activity and infectivity 
(Skehel and Wiley 2000). Both NA and HA are frequently 
mutated in the life cycle of the influenza virus, resulting 
in high levels of antigenic variation (Domingo and Hol-
land 1997).
The high mutation rate of HA sometimes generates 
new HA subtypes that have never infected humans. 
Some mutations have already been reported to contrib-
ute to the changes in the binding abilities of HA from 
avian to human receptors or from human to avian recep-
tors, which were, in part, responsible for the pandemic 
(Stevens et al. 2006). Inhibition of HA prevents the infec-
tion as a first attack caused by influenza virus mutants. 
Various methods including phage display have been used 
to screen for inhibitors that bind to the target domains 
(Hawkins et  al. 1992; Matsubara et  al. 2010; Krag et  al. 
2006); however, these current approaches would not be 
sufficient to deal with influenza viruses for the following 
reasons. Firstly, in order to discriminate the binding abili-
ties of HA mutants, purified HA needs to be immobilized 
on plastic wells or carriers (Hawkins et al. 1992; Matsub-
ara et al. 2010). Secondly, frequent mutations make it dif-
ficult to deal with HA mutants because time-consuming 
methods are required for each mutant preparation. In 
order to address these problems, a novel method for 
dealing with the high mutation rate of the influenza virus 
must be developed.
We previously reported on the successful display of 
various head domains of the wild-type and drug-resistant 
NAs from the avian H5N1 virus on yeast cell surface 
using yeast cell surface engineering in Saccharomyces 
cerevisiae (Shigemori et  al. 2013). In this system, a pro-
tein of interest can be displayed on yeast cell surface as 
a fusion protein with α-agglutinin, which is a cell wall 
protein involved in mating (Murai et al. 1997; Ueda and 
Tanaka 2000). This method allows direct measurement 
of the protein activity without protein purification steps 
(Ueda and Tanaka 2000).
Here, we report on the construction of two kinds of 
yeasts displaying either human short HA (hSHAα2,6) 
or human long HA (hLHAα2,6) from the human H1N1 
virus. hSHAα2,6 consists of the domain that binds to 
α2,6-linked sialic acid side chains, while hLHAα2,6 con-
sists of the binding domain and the stem region with-
out the secretion signal peptide and the transmembrane 
domain. hSHAα2,6 and hLHAα2,6 displayed on the yeast 
cell surface were shown to recognize α2,6-linked sialic 
acid side chains on the surface glycoproteins of eryth-
rocytes. The cell surface display of human HA mutants 
with altered binding specificity by induction of mutations 
was furthermore shown to result in direct detection of 
recognizing α2,3-linked sialic acid side chains on chicken 
erythrocytes. The system reported on here was shown 
to rapidly prepare HA mutants on cell surface and to 
allow for easy analysis of the functions of these mutants 
coupled with easy genetic manipulation of yeast. Our 
yeast cell surface system therefore allows for the simple 
and comprehensive construction of HA and NA mutant 
libraries on yeast cell surface, thereby facilitating the pre-
vention of pandemic caused by influenza viruses.
Materials and methods
Microbial strains and culture media
The DH5α (F−, endA1, hsdR17[rk−/mK+], supE44, thi-1, λ−, 
deoR, recA1, gyrA96, phoA, φ80dlacZΔM15, Δ[lacZYA-
argF]U169) Escherichia coli strain (Toyobo, Osaka, Japan) 
was used as the host for recombinant DNA manipula-
tion. S. cerevisiae BY4741/sed1Δ (MATa, his3Δ1, leu2Δ0, 
met15Δ0, ura3Δ0, YDR077w::KanMX4) (EUROSCARF, 
Frankfurt, Germany) was used for displaying HA. E. 
coli transformants were grown at 37 °C in Luria–Bertani 
medium (1  % [w/v] tryptone, 0.5  % [w/v] yeast extract, 
and 1  % [w/v] sodium chloride) containing 50  μg/mL 
ampicillin. Yeast transformants were selected on a syn-
thetic dextrose (SDC) solid medium (0.67 % [w/v] yeast 
nitrogen base without amino acids, 2  % [w/v] glucose, 
1 % [w/v] casamino acids, 0.002 % [w/v] adenine, 0.002 % 
[w/v] l-tryptophan, 2  % [w/v] agar). Isolated transfor-
mant colonies were aerobically cultivated at 30  °C in a 
liquid SDC medium buffered with 5  mM 2-morpholi-
noethanesulfonic acid (MES; pH 6.5).
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Vectors for cell surface display of human HA
The primers used in this study are listed in Additional 
file  1: Table S1. The human HA gene was derived from 
the Influenza A H1N1 (A/New Caledonia/20/99) HA 
ORF mammalian expression plasmid (Sino Biological, 
Beijing, China). The DNA fragments encoding a bind-
ing domain (human short HA, amino acid residues No. 
36–268) or encoding a binding domain and stem region 
(human long HA, amino acid residues No. 14–515) were 
PCR-amplified from the plasmid using the appropriate 
primers (“human short HA Forward” and “human short 
HA Reverse” for human short HA, or “human long HA 
Forward” and “human long HA Reverse” for human long 
HA). The DNA fragments were inserted into BglII/XhoI-
digested pULD1 (Kuroda et al. 2009), which encodes the 
C-terminal half of α-agglutinin downstream of the mul-
tiple cloning sites, using an In-Fusion HD Cloning kit 
(Clontech, Mountain view, CA). The resultant plasmids 
were named pULD-hSHAα2,6 and pULD-hLHAα2,6. The 
plasmids used for displaying the head domain recogniz-
ing α2,3-linked sialic acid side chains on surface glyco-
proteins were constructed by mutating pULD-hSHAα2,6 
or pULD-hLHAα2,6 using a QuikChange Site-Directed 
Mutagenesis kit (Agilent Technologies, Santa Clara, 
CA) and the “N190E Forward” and “N190E Reverse” or 
“D225G Forward” and “D225G Reverse” primers. The 
resultant plasmids were named pULD-hSHAα2,6* and 
pULD-hLHAα2,6*, respectively. pULD1-strep displaying a 
strep-tag instead of a FLAG-tag, was used as a negative 
control for immunofluorescence staining (Kuroda et  al. 
2009).
Transformation of yeast
Yeasts were transformed using the Frozen-EZ Yeast 
Transformation-II kit (Zymo Research, Irvine, CA). After 
the introduction of plasmids, the yeast transformants 
were selected on a uracil-deficient SDC solid medium.
Collection and preparation of red blood cells
Rabbit, chicken, horse (Nippon Biotest Laboratories, 
Tokyo, Japan), and swine (Funakoshi, Tokyo, Japan) 
erythrocytes were used for the HA assay. Aliquots (4 mL) 
of erythrocytes were washed three times with phosphate-
buffered saline (PBS; pH 7.4) by centrifugation at 100×g 
for 10 min, and were then resuspended in PBS (pH 7.4) at 
final working solution (1.0 %).
Hemagglutination assay
Yeast transformants were precultivated in buffered 
SDC medium (pH 6.5) for 24  h and the main cultiva-
tion was initiated at an initial optical density (OD600) of 
0.1 in 10 mL buffered SDC medium (pH 6.5). After 72 h 
cultivation at 30  °C, the cells were harvested and resus-
pended to 2.0  ×  108 cells/mL. Cell suspensions (50  µL) 
were diluted 2-, 4-, and 8-fold with PBS (pH 7.4) in a 
96-well microplate (FALCON 353910, CA). The yeast cells 
were mixed with 50  μL erythrocyte suspension (1.0  %) 
and incubated at 25  °C for 2  h. Active HA yields the 
“cross-linked structure”, while HA lacking binding ability 
forms “dot-like aggregation” in the center of the well (see 
Fig. 2). To investigate the relative binding abilities of HA, 
a quantitative analysis of dot-like aggregation in the well 
was performed using ImageJ software (National Institutes 
of Health, MD) (Lazic 2009). Images were analyzed after 
background correction using the rolling ball radius tool 
(50 pixels). The area of “dot-like aggregation” of erythro-
cytes within each negative control well (OD600 = 10) was 
defined as the measurement area, which was then used 
to evaluate erythrocyte levels as raw integrated density 
values (sum of pixel values) in other wells (OD600 =  10) 
(Lazic 2009). The results of this analysis were shown as 
the ratio to negative controls from each of six separate 
images (Additional file 1: Figure S1). Differences found to 
be significant by the Steel–Dwass test (P < 0.01) were con-
sidered to be indicative of HA binding ability.
Immunofluorescent staining
A total of 3.0 ×  107 yeast cells were washed once with 
1 mL PBS (pH 7.4) and then resuspended in PBS (pH 7.4) 
containing 1.0 % (w/v) bovine serum albumin. The yeast 
cells were incubated at room temperature for 30  min 
with rotary shaking (25  rpm; RT-50, TAITEC, Saitama, 
Japan). The yeast cells were incubated with an anti-FLAG 
M2 mouse monoclonal antibody (Sigma–Aldrich, MO) 
at a 1:300 dilution for 1.5  h at room temperature. The 
yeast cells were washed with PBS (pH 7.4) and mixed 
with Alexa Flour 488-conjugated anti-mouse IgG anti-
body (Invitrogen, Carlsbad, CA) at a 1:300 dilution for 
1 h at room temperature. After washing twice with PBS 
(pH 7.4), the yeast cells were resuspended to 108 cells/
mL by PBS (pH 7.4) for fluorescence observation. Fluo-
rescence was detected using an inverted microscope 
(Olympus IX71, Tokyo, Japan) through a U-MNIBA2 
mirror unit with a BP470–490 excitation filter, DM505 
dichroic mirror, and a BA510–550 emission filter (Olym-
pus). Live images were obtained using Aqua-Cosmos 2.0 
software (Hamamatsu Photonics, Shizuoka, Japan) con-
trolling a digital charge-coupled device camera (C4742-
95-12ER, Hamamatsu Photonics). To determine the 
display efficiency, the fluorescence intensities were meas-
ured by using a Fluoroskan Ascent Fluorometer (Lab-
systems, Helsinki, Finland) with excitation and emission 
wavelengths of 485 and 527  nm, respectively. A total of 
2.0 × 107 yeast cells were used for measurement.
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Results
Display of human HAs on the yeast cell surface
The HA0 protein of influenza viruses reportedly needs 
to be cleaved by host proteases to yield two subunits, 
HA1 and HA2 (Skehel and Wiley 2000; Stieneke-Grober 
et al. 1992). In the current study, two kinds of yeasts dis-
playing human short HA (hSHAα2,6) and human long 
HA (hLHAα2,6) were constructed (Additional file  1: Fig-
ure S2). hSHAα2,6 contains only the α2,6-linked sialic 
acid binding site (HA1), while hLHAα2,6 contains both 
the sialic acid binding site and the stem domain (HA1 
and HA2) (Fig.  1a). Fluorescent signals due to hHAsα2,6 
(hSHAα2,6 and hLHAα2,6) were detected on the yeast cell 
surface following immunofluorescence staining (Fig. 1b); 
however, the fluorescence intensity from yeast cells dis-
playing hLHAα2,6 was lower than that of yeast cells dis-
playing hSHAα2,6 (Fig.  1c). These results indicate that 
both hHAsα2,6 (hSHAα2,6 and hLHAα2,6) were correctly 
displayed, although hSHAα2,6 displayed more efficiently 
than hLHAα2,6.
Binding abilities of yeast‑displayed human HAs
The binding abilities of the human HAs displayed by 
yeast cells were confirmed by the hemagglutination assay 
described in “Materials and methods”. When active HA 
binds to sialic acid side chains on surface glycoproteins of 
Fig. 1 Display of HAs on yeast cell surfaces. a Scheme of yeast cell surface display of hHAsα2,6 and hHAsα2,6*. PI-PLC indicates phosphatidylinositol-
specific phospholipase C. hHAsα2,6* (hSHAα2,6* and hLHAα2,6*) represent the hHAsα2,6 with two point mutations (N190E and D225G). b Immuno-
fluorescence staining of the engineered yeast cells. Scale bars: 5 μm. c Comparison of the display efficiencies as relative fluorescence intensities 
following the immunofluorescence staining. Values represent mean ± standard error of the mean (SEM) based on three independent experiments
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erythrocytes, a “cross-linked structure” is formed, appearing 
as a uniform reddish color in the culture plate well. In the 
case of HA lacking these binding capabilities, on the other 
hand, the cross-linked structure is not formed, and “dot-
like aggregation” is formed in the center of the wells instead 
(Fig.  2). Rabbit erythrocytes, which have α2,6-linked sialic 
acid side chains on their surface glycoproteins (Tumpey 
et al. 2007), were initially used in this study. The hSHAα2,6 
and hLHAα2,6 displayed on yeast cell surface were found 
to form cross-linkages with the rabbit erythrocyte cells, 
while the yeast cells displaying only the FLAG-tag (nega-
tive control) did not form such cross-linkages (Fig. 3a). To 
evaluate the relative binding abilities of HA, the sum of 
pixel values within each well was measured as described in 
“Materials and methods”. Significant differences were meas-
ured between the negative control and hSHAα2,6 as well as 
between the negative control and hLHAα2,6 (Additional 
file 1: Figure S1). These results indicate that the HA-display-
ing yeasts recognized α2,6-linked sialic acid side chains on 
surface glycoproteins of rabbit erythrocytes.
Binding preferences of mutated human HAs on yeast cell 
surfaces
To further characterize HA on the yeast cell surface, we 
investigated whether the altered binding site affected the 
recognition properties of the displayed HA. On the virus 
surface, HA distinguishes between α2,3- and α2,6-linked 
sialic acid side chains (Ito et  al. 1997). In general, influ-
enza viruses isolated from humans bind to α2,6- but not 
α2,3-linked sialic acid side chains (Gagneux et al. 2003); 
however, the 190E and 225G mutations in HAs derived 
from the human H1 subtype reportedly yielded a change 
in recognition from α2,6- to α2,3-linked sialic acid side 
chains (Tumpey et al. 2007). Recognition change can be 
confirmed using erythrocytes from different hosts (Ito 
et  al. 1997). Chicken erythrocytes, for example, contain 
more α2,3- than α2,6-linked sialic acid side chains, while 
rabbit erythrocytes contain mainly α2,6-linked sialic acid 
side chains (Tumpey et al. 2007). We investigated in this 
study whether the introduction of two point mutations 
(N190E and D225G) into hHAsα2,6 altered the recogni-
tion from α2,6- to α2,3-sialic acid side chains. Human-
based short HA (hSHAα2,6*) and human-based long HA 
(hLHAα2,6*) were constructed by introducing the two 
point mutations (N190E and D225G) into hSHAα2,6 
and hLHAα2,6 (Additional file  1: Figure S2). Display of 
hSHAα2,6* and hLHAα2,6* on yeast cells was confirmed 
by immunofluorescence (Fig. 1b, c). The yeast-displayed 
hSHAα2,6* and hLHAα2,6* exhibited binding capabilities 
for α2,3-linked sialic acid side chains on surface glycopro-
teins of erythrocyte derived from chicken, while hHAsα2,6 
did not (Fig. 3b; Additional file 1: Figure S1). Therefore, 
the two point mutations were shown to alter recognition 
from α2,6- to α2,3-linked sialic acid side chains, suggest-
ing that the HAs on yeast cell surfaces exhibited similar 
binding characteristics to those of native HAs on the 
virus.
Fig. 2 Scheme of hemagglutination assay. “Cross-linked structures” 
and “dot-like aggregation” are illustrated
Fig. 3 Hemagglutination assay results. a Rabbit erythrocytes, b 
chicken erythrocytes, c horse erythrocytes, and d swine erythrocytes. 
Yeast cells were diluted from 10 to 2.5 of OD600
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The binding preferences of hHAsα2,6 and hHAsα2,6* 
(hSHAα2,6* and hLHAα2,6*) toward horse and swine eryth-
rocytes were investigated. Horse erythrocytes contain 
mainly α2,3-linked sialic acid side chains on surface gly-
coproteins and swine erythrocytes contain both α2,3- 
and α2,6-linked sialic acid side chains on their surface 
glycoproteins (Ito et  al. 1997). hHAsα2,6* was shown to 
form cross-linkages with the horse erythrocytes (Fig. 3c; 
Additional file 1: Figure S1) and in the case of the swine 
erythrocytes, both hHAsα2,6 and hHAsα2,6* formed cross-
linkages (Fig.  3d; Additional file  1: Figure S1). Overall, 
hHAsα2,6 were therefore shown to recognize rabbit and 
swine erythrocytes, while hHAsα2,6* was shown to recog-
nize chicken, horse, and swine erythrocytes. These recog-
nition specificities are consistent with the distribution of 
sialic acid side chains on the respective surface glycopro-
teins (Ito et al. 1997; Medeiros et al. 2001).
Discussion
In this study, the binding sites of hHAsα2,6 and hHAsα2, 6* 
were successfully displayed on yeast cell surface (Fig. 1b). 
The binding abilities of the displayed hHAsα2,6 were evalu-
ated by hemagglutination assay using rabbit erythrocytes 
whose surface glycoproteins contain α2,6-linked sialic 
acid side chains (Fig.  3a; Additional file  1: Figure S1). 
Altered recognition of HA to α2,3-linked sialic acid side 
chains was achieved by mutagenesis (Fig.  3b: Additional 
file  1: Figure S1). The displayed hHAsα2, 6* recognized 
α2,3-linked sialic acid side chains of chicken erythrocyte 
surface glycoproteins. The relative binding abilities of 
hHAsα2,6 and hHAsα2,6* toward erythrocytes derived from 
various species were assessed, and differences between 
HAs and negative controls, significant by the Steel–Dwass 
test (P  <  0.01), were considered indicative of binding 
capacity of the HA in question (Additional file 1: Figure 
S1). Chicken erythrocytes contain mainly α2,3- and α2,6-
linked sialic acid side chains of surface glycoproteins 
(Medeiros et  al. 2001). In this study, hHAsα2,6 did not 
form cross-linkages with chicken erythrocytes (Fig.  3b; 
Additional file  1: Figure S1) and the number of α2,6-
linked sialic acid side chains on the chicken erythrocytes 
was thus considered insufficient for cross-linkages to form 
(Table 1). The hHAsα2,6* formed cross-linkages with horse 
erythrocytes (Fig. 3c; Additional file 1: Figure S1) and both 
the hHAsα2,6 and the hHAsα2,6* formed cross-linkages 
with swine erythrocytes (Fig. 3d; Additional file 1: Figure 
S1). These findings suggest that the two amino acid sub-
stitutions ((N190E and D225G) in the HAs on the yeast 
cell surfaces altered the HA binding preferences, which is 
in agreement with previously reported findings (Ito et al. 
1998). These results demonstrate that the yeast cell sur-
face display system described here is a promising strategy 
for preparing functional HA mutants.
In the yeast cell surface engineering reported here, 
both hSHAα2,6 and hLHAα2,6 were successfully displayed 
on the yeast cell surface (Fig.  1b). Both hSHAα2,6 and 
hLHAα2,6 were shown to have similar binding capabili-
ties (Fig. 3a; Additional file 1: Figure S1), suggesting that 
the yeast-displayed hLHAα2,6 did not require protease-
mediated cleavage for its binding capabilities (Stevens 
et al. 2006). Glycan arrays have been used to investigate 
the binding abilities of HA (Stevens et  al. 2006; Kumari 
et al. 2007). For such glycan arrays, HA cleavage by pro-
tease treatments was not required for assessments of 
the binding abilities of HA (Stevens et al.  2006; Kumari 
et  al. 2007). Similarly, HAs displayed on yeast cell sur-
faces exhibited binding abilities without HA processing 
by exogenous proteases. Unlike glycan arrays (Stevens 
et  al. 2006; Kumari et  al. 2007), yeast cell surface engi-
neering does not require time-consuming purification 
and immobilization steps. In glycan arrays, HA must be 
directly or indirectly labelled with a fluorescent tag to 
allow for binding events to be detected (Stevens et  al. 
2006). Because of the weak affinity of HA for sialic acids 
of proteins, glycan arrays sometimes fail to detect bind-
ing events (Stevens et  al. 2006; Sauter et  al. 1989). The 
display of HA on yeast cell surfaces, on the other hand, 
may represent a convenient approach by which HA bind-
ing specificities can be confirmed.
Recombinant baculoviruses are widely used to express 
HA genes in cultured insect cells (Wang et  al. 2006; 
Treanor et al. 2013); however, HA production using this 
approach may take more than a month (Wang et al. 2006; 
Treanor et  al. 2013). With the yeast display method, on 
the other hand, HA can be prepared within several days 
and does not require purification.
Human HA consisting of only the binding site (hSHA) 
was displayed approximately 1.5 times more effectively 
than human HA consisting of both the binding site and 
the stem region (hLHA) (Fig. 1b, c). The molecular mass 
of displayed proteins on the yeast cell surface affects 
fluorescence intensities of cells after immunofluorescent 
staining (Nishitani et al. 2010; Shibasaki et al. 2001). Both 
Table 1 Hemagglutination assay with  erythrocytes 
from different animal species
“+” indicates positive binding abilities and “−” indicates no abilities
a Distribution of sialic acid-side chains on surface glycoproteins of the 
erythrocytes from animal species (Ito et al. 1997; Medeiros et al. 2001)
Hemagglutination with erythrocytes from
Rabbit Chicken Horse Swine
Relative abundancea α2, 6 α2, 6 << α2, 3 α2, 3 α2, 6 = α2, 3
Binding activity of HAsα2,6 + − − +
Binding activity of HAsα2,6* − + + +
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hSHA and hLHA exhibited binding abilities; however, 
hLHA-displaying yeasts would be more useful in inhibi-
tor screening assays since it is more likely that inhibitors 
would bind not only to the binding site but also to the 
stem region.
In conclusions, a yeast cell surface system reported on 
here allows for direct measurement of the binding abili-
ties of HAs without protein purification steps and thus 
would allow for the preparation of an HA mutant library 
as well as an NA mutant library as previously reported 
(Shigemori et al. 2013). This application would be advan-
tageous in the analysis of newly emerging influenza virus 
mutants, thereby contributing to the prompt develop-
ment of antiviral drugs. This yeast cell surface display 
system would therefore contribute to the prevention 
of influenza virus pandemics caused by frequent viral 
mutations.
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